The acquisition of infection, by hospitalized patients, with an extendedspectrum b-lactamase (ESBL)-producing organism is associated with increased patient morbidity, mortality and length of hospital stay . Notably, the recent worldwide emergence of carbapenemases, as well as modifications to outer-membrane permeability and upregulation of efflux systems, in association with ESBLs and AmpC b-lactamases, further limits treatment options (Nordmann et al., 2009) . Studies have shown that CTX-M-1 and -9 are the most common types of ESBLs found in Ireland (Morris et al., 2009) . The aim of this study was to evaluate the clinical features, molecular epidemiology, transmission, risk factors and outcomes of patients colonized or infected with ESBL-producing Enterobacteriaceae in order to improve patient management in this particular high-risk group.
Connolly Hospital Blanchardstown is a 350-bed general teaching hospital in Dublin, Ireland. From January 2009 to June 2011, 171 patients were newly identified as being either colonized or infected with an ESBL-producing Enterobacteriaceae from routine clinical specimens sent to the microbiology laboratory. The majority of these patients (79 %) were general practice or nursinghome/long-term-care patients and were not admitted to hospital. However, 36 patients (21 %) were identified as having acquired an ESBL-producing Enterobacteriaceae (detected more than 48 h post-admission) within the hospital and were the focus of this study. Of note, patients were not screened for carriage of ESBL-producing organisms upon admission or during their hospital stay. The first isolate detected from each patient was included in the study. Clinical data, including demographic variables, history of antibiotic use and patient risk factors for acquiring colonization/infection with an ESBLproducing organism, were recorded by medical chart analyses. Clinical evaluation of whether patients were colonized or infected with an ESBLproducing organism was based on retrospective medical chart review by a consultant clinical microbiologist.
Clinical isolates were confirmed as ESBL producers by both growth on Brilliance ESBL agar and the combination disk method. Reference strains included the American Type Culture Collection (ATCC) strains Escherichia coli ATCC 25922, E. coli ATCC 35218 and Klebsiella pneumoniae ATCC 700603. Genomic DNA was isolated from reference strains and clinical isolates using the Promega Wizard Genomic DNA Purification kit. ESBL genes bla TEM , bla SHV and bla CTX-M were amplified using multiplex PCR as described by Monstein et al. (2007) . A separate multiplex PCR was used to detect bla CTX-M genes encoding CTX-M-1, -2, -8, -9 and -25 in the clinical isolates (Woodford et al., 2006) . The phylogenetic relatedness of the clinical isolates was determined by multiplex PCR to detect the chuA and yjaA genes and the DNA fragment TSPE4.C4, as described by Clermont et al. (2000) . Clinical isolates were analysed by pulsed-field gel electrophoresis (PFGE) according to the PulseNet standardized laboratory protocol for E. coli (Ribot et al., 2006) . PFGE was used to compare UK Strain A (NCTC 13441), the UK's main circulating strain of ESBL-producing E. coli, with the study isolates. Macrorestriction patterns were analysed using GelCompar II software (version 6.5). The extent of variability was determined with the Dice coefficient using a tolerance of 1 % and strains were clustered according to the unweighted pair-group method with arithmetic mean.
Clonal groups were assigned based on similarity ¢85 %.
A total of 36 patients were identified as colonized or infected with an ESBLproducing Enterobacteriaceae while inpatients during the study period; 33 isolates from these patients were E. coli and three were K. pneumoniae. Patient demographics, clinical characteristics and clinical outcomes are detailed in Table 1 . The mean number of hospitalizations of the patients included in the study within the previous 6 months was 1.16 . Antibiotic use during their hospital stay (within 3 months of isolation of ESBL-producing organisms) and at the time of isolation of ESBL-producing Enterobacteriaceae indicated that the mean time between commencement of antibiotic therapy and isolation of an ESBL-producing Enterobacteriaceae was 24 days. Within the 3 months prior to identification of the ESBL-producing Enterobacteriaceae, 25 of the 36 patients (76 %) had received antibiotic therapy, of which 68 % of patients had received penicillin (or a penicillin derivative), 12 % had received a cephalosporin and 24 % had received a quinolone antibiotic. At the time of isolation, 14 of the 36 patients (42 %) were receiving antibiotics, of whom 50 % were receiving a penicillin (or a penicillin derivative), 14 % a cephalosporin and 14 % a quinolone antibiotic. A significant number of isolates included in this study were resistant to antibiotics commonly used for the treatment of infection with an ESBL-producing organism; for example, 72 % of isolates were resistant to ciprofloxacin and 33 % were resistant to one or more aminoglycosides. Of the 64 antibiotics prescribed to patients during their hospital stay (prior to or upon identification of an ESBL-producing Enterobacteriaceae), 10 (16 %) were not compliant with Connolly Hospital guidelines for the use of antibiotics. Of the patients IP: 54.70.40.11
On: Thu, 27 Dec 2018 10:44:04 included in this study, 64 % were colonized and 36 % infected with an ESBL-producing organism; all patients infected with an ESBLproducing organism were treated successfully. At the time of chart review, 70 % of patients were discharged from hospital, 24 % were deceased (none because of infection with an ESBL-producing organism) and 6 % remained inpatients.
Thirty-four of the 36 isolates (94.4 %) contained a bla CTX-M gene; bla CTX-M-1 was the most common gene cluster (26/34, 76.5 %), with the remainder being bla CTX-M-9 (8/34, 23.5 %). The two remaining isolates contained bla TEM and bla SHV genes. Two of the three K. pneumoniae isolates contained a bla CTX-M/TEM/SHV gene, while the remaining isolate contained a bla SHV gene. Eighteen of the 33 (55 %) E. coli isolates shared ¢85 % similarity. Seven clonal groups were identified (clonal groups 1-7) using the criterion of ¢85 % similarity. Clonal group 3 had four members, with identical PFGE patterns to UK Strain A, and the other groups had two or three members each. Group seven contained three isolates, with two isolates being 100 % identical to each other. These two isolates were recovered from two catheter stream urine specimens from two patients in the same room and were collected only 48 h apart, indicating probable cross-transmission. Review of ward and molecular-typing data identified no direct This study describes the clinical features and molecular epidemiology of ESBLproducing E. coli and K. pneumoniae identified from clinical specimens sent to the microbiology laboratory from inpatients in a teaching hospital over 29 months. The absence of a control group prohibits statistical comparison, but nevertheless key features of transmission of ESBL-producing Enterobacteriaceae within a hospital setting are reported. The majority of patients (78 %) were older than 65 years and presented with comorbidities, the most common of which were chronic respiratory disease, congestive heart failure and diabetes mellitus. The majority of organisms included in this study were isolated from either catheter stream urine (47 %) or mid-stream urine (28 %) samples sent to the microbiology laboratory. Risk factors associated with infection with an ESBL-producing organism have been described elsewhere (Apisarnthanarak et al., 2008) and include some that were prevalent among this cohort of patients, such as urinary catheterization, residency in a nursing home and a previous hospital admission or outpatient/day procedure within the past 6 months. Overall, 73 % of patients included in this study had a urinary catheter in situ and 47 % of isolates included were from catheter stream urine; this is reflective of the elderly patient population included (median age 76.5 years) and is in keeping with urinary catheterization being a significant risk factor for the acquisition of ESBLproducing organisms. This also highlights the requirement for regular review of the need for ongoing urinary catheterization among all patients within hospitals.
Although the patients included in this study were not routinely screened for carriage of ESBL-producing organisms on admission, the mean length of stay prior to isolation of an ESBL-producing organism for all patients was 61 days and the mean number of days between commencement of antibiotic therapy in hospital and isolation of an ESBL-producing organism was 24 days; therefore, risk factors identified in this study represent risks for acquiring ESBL-producing Enterobacteriaceae in hospital. Furthermore, patients who were both colonized and infected with an ESBLproducing organism were included in this study, as colonization with an ESBLproducing organism has been shown to increase the subsequent risk of infection (Ben-Ami et al., 2008) .
High levels of resistance to agents commonly used in the treatment of infection with an ESBL-producing organism, such as quinolones and aminoglycosides, demonstrates the complexity and challenges in treating these patients and is of significant concern. The majority of patients had been exposed to a b-lactam and/or b-lactamase inhibitor during the previous 3 months or during their hospital stay and, furthermore, retrospective chart review found that 16 % of such antibiotic use was not compliant with local antibiotic prescribing guidelines. Acquisition of ESBL-producing Enterobacteriaceae resulted in colonization rather than infection in the majority of patients, but nevertheless represents an ongoing risk of infection for the patient and cross-transmission within the healthcare environment. The ESBL gene bla CTX-M was predominant in the study isolates with the CTX-M-1 cluster being most prevalent, followed by CTX-M-9. This pattern is similar to that reported previously and indicates a change from a predominance of TEM-and SHVproducing strains in Ireland to a predominance of CTX-M-producing strains, specifically the CTX-M-1 gene cluster (Morris et al., 2009) . This pattern has also been seen in other European countries (Markovska et al., 2008) . PFGE analysis and phylogenetic typing showed that phylogenetic groups were associated with specific clonal groups. Strong similarity between the predominant circulating UK and Irish ESBL-producing E. coli was indicated by PFGE analysis.
Two isolates, with 100 % similarity, from clonal group 6 were isolated from the same ward over a 2 month period. Furthermore, two isolates from clonal group 7, again with 100 % similarity, were isolated from patients in the same room within 48 h of each other, while the other member of clonal group 7 was isolated from the same ward 1 month previously. These data indicate the probability of crosstransmission or an environmental reservoir on these wards, which would not have been detected without the combination of accurate epidemiological data and molecular characterization. There is an urgent need for ongoing characterization of ESBL-producing isolates to quickly identify crosstransmission in real time and to intervene to prevent further spread or recurrence.
This study highlights important epidemiological and molecular data regarding transmission of ESBL-producing Enterobacteriaceae within a hospital setting. Acquisition of ESBL-producing Enterobacteriaceae for the patients in this study likely reflects a combination of antibiotic exposure, interventions such as urinary catheterization and crosstransmission. Healthcare professionals need to consider the potential risk factors for colonization with an ESBL-producing organism upon hospital admission. A multifactorial approach, such as ensuring patients are not unnecessarily catheterized, prudent antibiotic prescribing, maintaining a clean ward environment, strict adherence to hand hygiene guidelines and the availability of timely molecular characterization to track the spread of bacteria, is required to minimize the risk of transmission of multidrug-resistant organisms.
